# Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS

> **NCT04165850** · PHASE2 · COMPLETED · sponsor: **NeuroSense Therapeutics Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** Fixed dose combination Ciprofloxacin/Celecoxib

## Key facts

- **NCT ID:** NCT04165850
- **Lead sponsor:** NeuroSense Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-25
- **Primary completion:** 2021-01-19
- **Final completion:** 2021-01-19
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04165850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04165850, "Open Label Study to Evaluate Ciprofloxacin/Celecoxib Combination in Patients With ALS". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04165850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*